| |
|
|
|
|
|
|
|||
|
Blood, 15 April 2004, Vol. 103, No. 8, pp. 3122-3130. Prepublished online as a Blood First Edition Paper on December 4, 2003; DOI 10.1182/blood-2003-07-2500.
Submitted July 24, 2003
Department of Hematology, AZ-VUB, Brussels, Belgium * Corresponding author; email: christian.demanet{at}az.vub.ac.be.
HLA class I antigen defects may have a negative impact on the growing application of T cell-based immunotherapeutic strategies for treatment of leukemia. Therefore in the present study taking advantage of a large panel of HLA class I allele-specific human monoclonal antibodies we have compared HLA class I antigen expression on leukemic cells with that on autologous and allogeneic normal cells. Downregulation of HLA-A and/or -B allospecificities was present in the majority of the patients studied. However, downregulation did not affect all HLA class I alleles uniformly, but was almost exclusively restricted to HLA-A allospecificities and to HLA-B allospecificities which belong to the HLA-Bw6 group. The latter allospecificities, at variance from those which belong to the HLA-Bw4 group, do not modulate the interactions of leukemic cells with NK cells. Therefore our results suggest that the selective downregulation of HLA-A and HLA-Bw6 allospecificities associated with HLA-Bw4 preservation provides leukemic cells with an escape mechanism not only from CTL, but also from NK cells. As a result T cell-based immunotherapeutic strategies for leukemia should utilize HLA-Bw4 alloantigens as restricting elements since a selective HLA-Bw4 allele loss would provide leukemic cells with an escape mechanism from CTL, but would increase their susceptibility to NK cell-mediated lysis.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||